Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LASIX vs EDECRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Furosemide inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption and increasing urinary output.
Ethacrynic acid inhibits the Na-K-Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to diuresis.
Edema associated with congestive heart failure, cirrhosis of the liver, and renal disease including nephrotic syndrome,Hypertension (off-label)
Treatment of edema associated with congestive heart failure, cirrhosis, and renal disease,Treatment of hypertension (off-label),Treatment of ascites (off-label),Management of hypercalcemia (off-label)
20-80 mg IV or PO once or twice daily; maximum 600 mg/day IV or PO.
Oral: 50-100 mg once or twice daily, maximum 400 mg/day. IV: 50 mg (0.5 mg/kg) once, may repeat once at 2-hour intervals if needed.
Terminal elimination half-life is approximately 1.5-2 hours. In renal impairment (Cr Cl <20 m L/min), half-life may prolong to up to 2-4 hours; in end-stage renal disease or heart failure, may exceed 4 hours.
Terminal elimination half-life is 2-4 hours; prolonged in renal impairment (up to 30 hours) and in heart failure.
Furosemide is metabolized primarily by glucuronidation via UGT1A1, with minimal hepatic metabolism; about 50% is excreted unchanged in urine.
Metabolized primarily in the liver, with approximately 30% excreted unchanged in urine and the remainder as metabolites, including the cysteine conjugate.
Primarily renal excretion (50-80% as unchanged drug) via glomerular filtration and proximal tubular secretion; minor fecal elimination (<5%).
Approximately 60-70% excreted unchanged in urine via glomerular filtration and tubular secretion; remaining 30-40% eliminated via biliary/fecal route.
91-99% bound, primarily to albumin.
Approximately 95-98% bound, primarily to albumin.
0.1-0.2 L/kg in healthy adults; increases in conditions with reduced plasma protein binding (e.g., nephrotic syndrome) or fluid overload (e.g., heart failure) up to 0.3-0.8 L/kg.
0.4-0.8 L/kg; reflects distribution primarily into extracellular fluid.
Oral: 60-70% (range 50-80%); decreased by food; intravenous: 100%.
Oral: approximately 50-70% due to first-pass metabolism; Intravenous: 100%.
GFR 10-50 m L/min: dose every 12 hours; GFR <10 m L/min: avoid use or use with extreme caution.
GFR 10-50 m L/min: 50% of normal dose. GFR <10 m L/min: not recommended or use with extreme caution.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated or avoid.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
1-2 mg/kg/dose PO or IV every 6-12 hours; maximum 6 mg/kg/day.
Oral: 1-3 mg/kg/day in 1-2 divided doses. IV: 1 mg/kg/dose, maximum 50 mg/dose.
Start at 20 mg/day PO or 20 mg IV, titrate slowly due to increased sensitivity and risk of electrolyte disturbances.
Start at lowest dose (25-50 mg oral daily) due to increased risk of electrolyte disturbances and hypotension.
Furosemide is a potent diuretic. If given in excessive amounts, it can lead to profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dose schedule must be adjusted to the individual patient's needs.
WARNING: EDECRIN is a potent diuretic which, if given in excessive amounts, can lead to profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dose schedule must be adjusted to the individual patient's needs.
Risk of hypovolemia, dehydration, and electrolyte imbalances (hypokalemia, hyponatremia, hypochloremia, hypomagnesemia, hypocalcemia),Ototoxicity, especially with rapid injection or severe renal impairment,Sulfonamide cross-sensitivity
Ototoxicity: Risk of hearing loss, especially with rapid IV administration or in patients with renal impairment; avoid concurrent use with other ototoxic drugs.,Volume and electrolyte depletion: Profound diuresis leading to dehydration, hypokalemia, hyponatremia, hypochloremia, and metabolic alkalosis.,Hypersensitivity reactions: Rash, eosinophilia, and anaphylaxis.,Gastrointestinal disturbances: Nausea, vomiting, diarrhea, and gastrointestinal bleeding (rare).,Hyperuricemia may precipitate gout.,Use with caution in patients with hepatic cirrhosis due to risk of hepatic encephalopathy.
Anuria,History of hypersensitivity to furosemide or sulfonamides
Anuria,Hypersensitivity to ethacrynic acid or any component of the formulation,Severe electrolyte depletion (e.g., hypokalemia, hyponatremia) until corrected,Concurrent use with other ototoxic agents (relative contraindication)
High sodium intake can counteract diuretic effects. Avoid excessive licorice consumption as it can worsen hypokalemia. Grapefruit juice may increase systemic exposure of furosemide; avoid concurrent use.
Avoid excessive intake of high-sodium foods as they can counteract the diuretic effect. Grapefruit juice may increase the risk of ototoxicity; consumption should be limited. Alcohol can exacerbate hypotension and dehydration. Ensure adequate potassium intake through diet (e.g., bananas, oranges) unless directed otherwise by a healthcare provider.
Furosemide crosses the placenta. First trimester: limited data, no clear teratogenic pattern; risk cannot be excluded. Second and third trimesters: may cause maternal hypovolemia, decreased placental perfusion, electrolyte imbalances, and fetal dehydration; oligohydramnios reported. Use only if clearly needed.
EDECRIN (ethacrynic acid) is classified as FDA Pregnancy Category B. Limited human data; animal studies have not demonstrated teratogenic effects. However, diuretic use during pregnancy may reduce placental perfusion. Fetal risks include electrolyte disturbances, volume depletion, and possible growth restriction. Use only if clearly needed.
Furosemide is excreted into breast milk in low amounts. M/P ratio approximately 1:1. No adverse effects reported in infants, but may suppress lactation. Use with caution, especially in neonates.
It is not known if ethacrynic acid is excreted in human milk. Due to potential adverse effects in the nursing infant, such as electrolyte imbalance, caution is advised. The manufacturer recommends discontinuing nursing or the drug, taking into account the importance of the drug to the mother. M/P ratio is unknown.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing furosemide exposure. Dose adjustments may be necessary to maintain efficacy; titration based on clinical response and monitoring recommended. No established dose modification guidelines; individualize therapy.
Pregnancy may alter pharmacokinetics; however, no specific dose adjustments have been established. Use lowest effective dose and shortest duration. Monitor for hypovolemia and electrolyte imbalances, which may be more pronounced in pregnancy.
For rapid diuresis in acute pulmonary edema, administer IV furosemide slowly over 1-2 minutes to avoid ototoxicity. Monitor serum potassium closely, especially in patients on digoxin or with hepatic cirrhosis. Higher doses (>80 mg) may require divided doses to prevent peak-related adverse effects.
EDECRIN (ethacrynic acid) is a potent loop diuretic that, unlike furosemide, is not a sulfonamide and can be used in patients with sulfonamide allergy. It can cause ototoxicity that is often irreversible, especially when given rapidly IV or with other ototoxic drugs like aminoglycosides. Monitor for hypokalemia, hypomagnesemia, and volume depletion. Use with caution in patients with hepatic cirrhosis due to risk of electrolyte-induced encephalopathy.
Take furosemide exactly as prescribed, usually in the morning to avoid nighttime urination.,Weigh yourself daily and report rapid weight gain or loss of more than 2-3 pounds in a day.,Avoid prolonged sun exposure and use sunscreen as furosemide can increase sun sensitivity.,Do not stop taking this medication abruptly; tapering may be needed to avoid rebound fluid retention.
Take this medication exactly as prescribed, usually once or twice daily.,Avoid alcohol and limit salt intake to reduce fluid retention.,Weigh yourself daily and report rapid weight gain or loss to your doctor.,Stand up slowly from sitting or lying down to prevent dizziness from low blood pressure.,Notify your doctor immediately if you experience hearing loss, ringing in the ears, or dizziness.,This drug may increase blood sugar; monitor if you have diabetes.,Avoid taking with other ototoxic medications like certain antibiotics without doctor approval.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LASIX vs EDECRIN, answered by our medical review team.
LASIX is a Loop Diuretic that works by Furosemide inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption and increasing urinary output.. EDECRIN is a Loop Diuretic that works by Ethacrynic acid inhibits the Na-K-Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to diuresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LASIX and EDECRIN depend on the specific clinical indication. These are both Loop Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LASIX is: 20-80 mg IV or PO once or twice daily; maximum 600 mg/day IV or PO.. The standard adult dose of EDECRIN is: Oral: 50-100 mg once or twice daily, maximum 400 mg/day. IV: 50 mg (0.5 mg/kg) once, may repeat once at 2-hour intervals if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LASIX and EDECRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LASIX is classified as Category C. Furosemide crosses the placenta. First trimester: limited data, no clear teratogenic pattern; risk cannot be excluded. Second and third trimesters: may cause maternal hypovolemia, . EDECRIN is classified as Category C. EDECRIN (ethacrynic acid) is classified as FDA Pregnancy Category B. Limited human data; animal studies have not demonstrated teratogenic effects. However, diuretic use during preg. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.